Background: There are no studies on prevalence, incidence and comorbidities of Parkinson's disease (PD) in the Italian population. Methods: The database of 700 Italian general practitioners (population, 923,356) was investigated. All patients with International Classification of Diseases Ninth Revision - Clinical Modification (ICD-9-CM) diagnosis of PD during the period 2002-2012 were included. Parkinsonisms were excluded. Clinical conditions preceding PD were identified through ICD-9-CM codes. The Charlson Comorbidity Index was used. PD crude and standardized prevalence and annual incidence were calculated. Crude and adjusted hazard ratios were calculated for comorbidities. Results: A total of 2,204 patients (1,140 men, 1,064 women, age 22-95 years) were included. The crude prevalence of PD was 239/100,000. Prevalence increased exponentially with age. Standardized prevalence was 233 (95% CI 232-235). One hundred ninety-four patients were newly diagnosed, giving a crude incidence of 22/100,000 and a standardized incidence of 23.1/100,000 (95% CI 22.9-23.2). Incidence increased steadily until age 75-84 years and then decreased. Older age, cardiovascular and gastrointestinal disorders, diabetes, and restless-legs syndrome were associated with increased PD risk and smoking and hypersomnia with decreased PD risk. The Charlson Comorbidity Index was associated with PD risk with a documented gradient. Conclusions: Prevalence and incidence of PD in Italy are in line with studies with the highest case ascertainment. PD risk varies with the number and type of comorbidities.

1.
Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J: Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011;26(suppl 1):S1-S58.
2.
de Lau LM, Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535.
3.
Pringsheim T, Jette N, Frolkis A, Steeves TD: The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583-1590.
4.
Casetta I, Granieri E, Govoni V, et al: Epidemiology of Parkinson's disease in Italy. A descriptive survey in the U.S.L. of Cento, province of Ferrara, Emilia-Romagna. Acta Neurol (Napoli) 1990;12:284-291.
5.
Morgante L, Rocca WA, Di Rosa AE, et al: Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian neuro-epidemiologic study (SNES) group. Neurology 1992;42:1901-1907.
6.
Beghi E, Monticelli ML, Sessa A, Simone P: The prevalence of parkinsonism in Italy: an epidemiological survey of the disease in general practice. The Italian general practitioner study group (IGPSG). Mov Disord 1994;9:403-408.
7.
Chiò A, Magnani C, Schiffer D: Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998;13:400-405.
8.
de Rijk MC, Launer LJ, Berger K, et al: Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 2000;54(11 suppl 5):S21-S23.
9.
Granieri E, Carreras M, Casetta I, et al: Parkinson's disease in Ferrara, Italy, 1967 through 1987. Arch Neurol 1991;48:854-857.
10.
Baldereschi M, Di Carlo A, Rocca WA, et al: Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA working group. Italian longitudinal study on aging. Neurology 2000;55:1358-1363.
11.
Csoti I, Jost WH, Reichmann H: Parkinosn's disease between internal medicine and neurology. J Neural Transm (Vienna) 2016;123:3-17.
12.
Istituto Centrale di Statistica: Classificazione Delle Malattie, Traumatismi e Cause di Morte, IX Revisione-1975. Roma, Luglio, 1984.
13.
Cricelli C, Mazzaglia G, Samani F, et al: Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003;25:254-257.
14.
Filippi A, Vanuzzo D, Bignamini AA, Mazzaglia G, Cricelli C, Catapano AL: The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J 2005;6:311-314.
15.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
16.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
17.
Totaro R, Marini C, Pistoia F, Sacco S, Russo T, Carolei A: Prevalence of Parkinson's disease in the L'Aquila district, central Italy. Acta Neurol Scand 2005;112:24-28.
18.
Kis B, Schrag A, Ben-Shlomo Y, et al: Novel three-stage ascertainment method: prevalence of PD and parkinsonism in South Tyrol, Italy. Neurology 2002;58:1820-1825.
19.
Hao K, Di Narzo AF, Ho L, et al: Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes. Mol Aspects Med 2015;43-44:66-76.
20.
Li JQ, Tan L, Wang HF, et al: Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry 2016;87:476-484.
21.
Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J: Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007;30:842-847.
22.
Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G: Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008;31:2003-2005.
23.
Becker C, Brobert GP, Johansson S, Jick SS, Meier CR: Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 2008;31:1808-1812.
24.
D'Amelio M, Ragonese P, Callari G, et al: Diabetes preceding Parkinson's disease onset. A case-control study. Parkinsonism Relat Disord 2009;15:660-664.
25.
Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G: Sleep disorders and the natural history of Parkinson's disease: the contribution of epidemiological studies. Sleep Med Rev 2011;15:41-50.
26.
Tandberg E, Larsen JP, Karlsen K: Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999;14:922-927.
27.
Braga-Neto P, da Silva-Júnior FP, Sueli Monte F, de Bruin PF, de Bruin VM: Snoring and excessive daytime sleepiness in Parkinson's disease. J Neurol Sci 2004;217:41-45.
28.
Wong JC, Schwarzschild MA, Ascherio A, Gao X: Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep 2014;37:369-372.
29.
Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M: Restless legs syndrome in Parkinson's disease. Parkinsonism Relat Disord 2014;20(suppl 1):S5-S9.
30.
Ondo WG, Vuong KD, Jankovic J: Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002;59:421-424.
31.
Gómez-Esteban JC, Zarranz JJ, Tijero B, et al: Restless legs syndrome in Parkinson's disease. Mov Disord 2007;22:1912-1916.
32.
Nomura T, Inoue Y, Miyake M, Yasui K, Nakashima K: Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord 2006;21:380-384.
33.
Krishnan PR, Bhatia M, Behari M: Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003;18:181-185.
34.
Loo HV, Tan EK: Case-control study of restless legs syndrome and quality of sleep in Parkinson's disease. J Neurol Sci 2008;266:145-149.
35.
Fereshtehnejad SM, Shafieesabet M, Shahidi GA, Delbari A, Lökk J: Restless legs syndrome in patients with Parkinson's disease: a comparative study on prevalence, clinical characteristics, quality of life and nutritional status. Acta Neurol Scand 2015;131:211-218.
36.
Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF: Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015;14:625-639.
37.
Ross GW, Abbott RD, Petrovitch H, Tanner CM, White R: Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 2012;18(suppl 1):S199-S202.
38.
Makaroff L, Gunn A, Gervasoni C, Richy F: Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database. J Parkinsons Dis 2011;1:65-74.
39.
Jain S, Goldstein DS: Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 2012;46:572-580.
40.
Noack C, Schroeder C, Heusser K, Lipp A: Cardiovascular effects of levodopa in Parkinson's disease. Parkinsonism Relat Disord 2014;20:815-818.
41.
Perez-Lloret S, Rey MV, Crispo J, et al: Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. Expert Opin Drug Saf 2014;13:351-360.
42.
Buoli M, Caldiroli A, Altamura AC: Psychiatric conditions in Parkinson disease: a comparison with classical psychiatric disorders. J Geriatr Psychiatry Neurol 2016;29:72-91.
43.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al: Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012;72:893-901.
44.
Bajaj A, Driver JA, Schernhammer ES: Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
45.
Liu R, Gao X, Lu Y, Chen H: Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011;76:2002-2009.
46.
Gorell JM, Johnson CC, Rybicki BA: Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994;44:1865-1868.
47.
Rizzo G, Copetti M, Arcuti S, Martino D, et al: Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 2016;86:566-576.
48.
Wermuth L, Lassen CF, Himmerslev L, Olsen J, Ritz B: Validation of hospital register-based diagnosis of Parkinson's disease. Dan Med J 2012;59:A4391.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.